Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2020 Results - Earnings Call Transcript

Alpine Immune Sciences, Inc. (ALPN) Q4 2020 Earnings Conference Call March 18, 2021 4:30 PM ET

Company Participants

Alex Sharif - Director, Investor Relations and Corporate Development
Mitchell Gold - Executive Chairman and Chief Executive Officer
Stanford Peng - President and Head of Research and Development
Paul Rickey - Chief Financial Officer

Conference Call Participants

Ted Tenthoff - Piper Sandler
Mark Breidenbach - Oppenheimer
Joe Pantginis - H.C. Wainwright

Operator

Good afternoon, ladies and gentlemen, and thank you for joining the Alpine Immune Sciences Fourth Quarter 2020 Financial Results and Corporate Update Conference Call. Currently all participants are in a listen-only mode. Following the management prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, Thursday, March 18th, 2021.

I would now like to introduce Alex Sharif, Director, Investor Relations and Corporate Development. Please go ahead.

Alex Sharif

Thank you, Josh. With me on today's call from Alpine Immune Sciences are; Executive Chairman and CEO, Dr. Mitchell Gold; President and Head of Research and Development, Dr. Stanford Peng; Chief Financial Officer, Paul Rickey; and Chief Business Officer, Dr. Remy Durand.

This afternoon Alpine Immune Sciences issued a press release announcing the company's fourth quarter and year end 2020 financial results and corporate update. If you have not received this news - this news release and would like to read it or if you would simply like to be added to the company's distribution list, you can do both on the Investor Relations page of the company's website at www.alpineimmunesciences.com.

During the course of today's conference call, Alpine's management will make forward-looking statements, including, but not limited to, statements regarding the company's preclinical and clinical development plans and the timing thereof, expectations regarding the sufficiency of cash to fund the operations, including any cash received from potential